October 11, 2019 - Burn specialists at Massachusetts General Hospital (MGH) announced today they have successfully used live-cell, genetically engineered pig skin (xenograft) for the temporary closure of a burn wound. Through an FDA-cleared phase one clinical trial led by surgeon Jeremy Goverman, MD, of the MGH Sumner Redstone Burn Service, this procedure marks the first-time pig tissue derived from an animal with gene edits has been transplanted directly onto a human wound.
December 8, 2018 - XenoTherapeutics, a life science company whose mission is to solve the global shortage of organs and tissues for transplants, announced today that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application (IND #18914) allowing clinical studies of Xeno-Skin™ to be initiated. Xeno-Skin is a first-of-its-kind xenotransplantation product, designed to provide a safe temporary coverage mechanism for patients with severe burn wounds. The company is inactive preparations to enroll patients for a first-in-human clinical study of Xeno-Skin at Massachusetts General Hospital (MGH) by the end of 2018. Learn More »
October 23, 2018 - XenoTherapeutics, a life science company developing the first non-human organ transplant solution currently under investigational review by the FDA, announced that company co-founders Paul Holzer, CEO and Jon Adkins, COO, along with a team of former military and first responder volunteers, traveled some 1500 miles from their homes in New Hampshire to deliver emergency aid in the immediate aftermath of Hurricane Michael.
October 5, 2018 - XenoTherapeutics, a life science company developing the first non-human organ transplant solution currently under investigational review by the FDA, announced that company co-founders Paul Holzer, CEO and Jon Adkins, COO presented an update on the company’s pre-clinical progress for its skin transplant solution at the 2018 Dan Morton Meeting of the Boston Area Pharmaceutical Toxicology Group. The conference, held today at the Novartis Institutes for BioMedical Research in Cambridge, hosted representatives from a variety of biotechnology companies on the cutting-edge of research and development. Learn More »
February 26, 2020 - XenoTherapeutics, a clinical-stage biotechnology company developing alternative gene therapies in xenotransplantation to supply living cells, tissues, and organs for patients in need, announced the hiring of Dr. Michael Yaremchuk to serve as its first Chief Medical Officer. In addition to advising XenoTherapeutics on clinical operations, Dr. Yaremchuk serves as Director of Craniofacial Surgery at the Massachusetts General Hospital (MGH), where XenoTherapeutics is currently conducting a Phase I clinical trial of its first product, Xeno-Skin™. Learn More »
April 4, 2019 - XenoTherapeutics, Inc., a regenerative medicine company specializing in xenotransplantation, received the Burke/Yannas Award for Best Bioengineering Paper today at the 51st conference of the American Burn Association for its research of Xeno-Skin™. Co-founders Paul Holzer, CEO and Jon Adkins, COO, accepted the award on the company’s behalf. Learn More »